Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oleg V Tcheremissine

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Expert Opinion on Drug Safety|November 6, 2008
Is quetiapine a drug of abuse? Reexamining the issue of addictionOleg V Tcheremissine
Innovations in Clinical Neuroscience|December 6, 2013
A case of paranoid schizophrenia and severe antipsychotic-induced Parkinson's disorder treated with a combination of olanzapine and lurasidoneOleg V Tcheremissine, Danielle Englert
CNS Drugs|June 28, 2006
Pharmacological aspects of the treatment of conduct disorder in children and adolescentsOleg V Tcheremissine, Lori M Lieving
Expert Opinion on Pharmacotherapy|October 4, 2005
Pharmacotherapy of postpartum depression: current practice and future directionsOleg V Tcheremissine, Lori M Lieving
Therapeutics and Clinical Risk Management|June 19, 2009
Once-daily medications for the pharmacological management of ADHD in adultsOleg V Tcheremissine, Lori M Lieving
Innovations in Clinical Neuroscience|September 28, 2016
Gabapentin Abuse in a Patient with Comorbid Mood and Substance Use DisordersOleg V Tcheremissine, Durga Prasad Bestha
Innovations in Clinical Neuroscience|June 7, 2017
Modafinil Augmentation Therapy in Patient with Traumatic Brain InjuryOleg V Tcheremissine, James C Rachal
Expert Opinion on Pharmacotherapy|May 14, 2008
Pharmacotherapy of adult attention deficit/hyperactivity disorder: review of evidence-based practices and future directionsOleg V Tcheremissine, J Octavio Salazar
Expert Opinion on Pharmacotherapy|May 25, 2004
Psychopharmacology of conduct disorder: current progress and future directionsOleg V Tcheremissine, Don R Cherek, Scott D Lane
Expert Opinion on Investigational Drugs|November 9, 2011
Targeting cognitive deficits in schizophrenia: a review of the development of a new class of medicines from the perspective of community mental health researchersOleg V Tcheremissine, Manuel A Castro, Dineen R Gardner
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Expert Opinion on Drug Safety|November 6, 2008
Is quetiapine a drug of abuse? Reexamining the issue of addictionOleg V Tcheremissine
Innovations in Clinical Neuroscience|December 6, 2013
A case of paranoid schizophrenia and severe antipsychotic-induced Parkinson's disorder treated with a combination of olanzapine and lurasidoneOleg V Tcheremissine, Danielle Englert
CNS Drugs|June 28, 2006
Pharmacological aspects of the treatment of conduct disorder in children and adolescentsOleg V Tcheremissine, Lori M Lieving
Expert Opinion on Pharmacotherapy|October 4, 2005
Pharmacotherapy of postpartum depression: current practice and future directionsOleg V Tcheremissine, Lori M Lieving
Therapeutics and Clinical Risk Management|June 19, 2009
Once-daily medications for the pharmacological management of ADHD in adultsOleg V Tcheremissine, Lori M Lieving
Innovations in Clinical Neuroscience|September 28, 2016
Gabapentin Abuse in a Patient with Comorbid Mood and Substance Use DisordersOleg V Tcheremissine, Durga Prasad Bestha
Innovations in Clinical Neuroscience|June 7, 2017
Modafinil Augmentation Therapy in Patient with Traumatic Brain InjuryOleg V Tcheremissine, James C Rachal
Expert Opinion on Pharmacotherapy|May 14, 2008
Pharmacotherapy of adult attention deficit/hyperactivity disorder: review of evidence-based practices and future directionsOleg V Tcheremissine, J Octavio Salazar
Expert Opinion on Pharmacotherapy|May 25, 2004
Psychopharmacology of conduct disorder: current progress and future directionsOleg V Tcheremissine, Don R Cherek, Scott D Lane
Expert Opinion on Investigational Drugs|November 9, 2011
Targeting cognitive deficits in schizophrenia: a review of the development of a new class of medicines from the perspective of community mental health researchersOleg V Tcheremissine, Manuel A Castro, Dineen R Gardner
Pageof 3